Fulgent Genetics (MEX:FLGT) Debt-to-EBITDA : -0.24 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fulgent Genetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was MXN49 Mil. Fulgent Genetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was MXN177 Mil. Fulgent Genetics's annualized EBITDA for the quarter that ended in Jun. 2024 was MXN-935 Mil. Fulgent Genetics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was -0.24.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Fulgent Genetics's Debt-to-EBITDA or its related term are showing as below:

MEX:FLGT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.31 Med: 0.05 Max: 1.59
Current: -0.27

During the past 10 years, the highest Debt-to-EBITDA Ratio of Fulgent Genetics was 1.59. The lowest was -0.31. And the median was 0.05.

MEX:FLGT's Debt-to-EBITDA is ranked worse than
100% of 101 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.57 vs MEX:FLGT: -0.27

Fulgent Genetics Debt-to-EBITDA Historical Data

The historical data trend for Fulgent Genetics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Debt-to-EBITDA Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

1.59

0.05

0.03

0.18

-0.31

Fulgent Genetics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.09	0.11	-0.16	-0.21	-0.24

Competitive Comparison of Fulgent Genetics's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Fulgent Genetics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulgent Genetics's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Debt-to-EBITDA falls into.

Fulgent Genetics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fulgent Genetics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(87.248	+	171.627)	/	-834.318
	=	-0.31

Fulgent Genetics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(49.464	+	176.752)	/	-934.544
	=	-0.24

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.

Fulgent Genetics (MEX:FLGT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Fulgent Genetics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.